UROY:NASDAQUranium Royalty Corp. Analysis
Data as of 2026-05-07 - not real-time
$3.96
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Uranium Royalty Corp. (UROY) is trading at $3.96, comfortably above its 20‑day (3.77), 50‑day (3.73) and 200‑day (3.76) simple moving averages, indicating short‑term momentum. The RSI sits at 56, suggesting neutral overbought/oversold conditions, while the MACD histogram is positive (0.034) and the MACD signal is bullish, reinforcing a modest upside bias. Support sits at $3.485 and resistance at $4.20, leaving the stock near the lower half of its range.
Fundamentally, the company is severely undervalued by discounted cash‑flow analysis, with a fair‑value estimate of $10.46 – more than double the current price, yielding a ~14% upside relative to analyst targets and a >150% upside versus intrinsic value. The recent agreement to acquire Sweetwater Royalties (≈$1.1 bn) and the Raymond James upgrade to Outperform with a new price target of C$6.25 provide a concrete growth catalyst. However, the stock exhibits high beta (≈2.0), 30‑day volatility of 60%, and decreasing volume, all of which flag elevated market risk.
Fundamentally, the company is severely undervalued by discounted cash‑flow analysis, with a fair‑value estimate of $10.46 – more than double the current price, yielding a ~14% upside relative to analyst targets and a >150% upside versus intrinsic value. The recent agreement to acquire Sweetwater Royalties (≈$1.1 bn) and the Raymond James upgrade to Outperform with a new price target of C$6.25 provide a concrete growth catalyst. However, the stock exhibits high beta (≈2.0), 30‑day volatility of 60%, and decreasing volume, all of which flag elevated market risk.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish MACD and price above short‑term SMAs
- Acquisition of Sweetwater Royalties as a catalyst
- Current price well below DCF fair value
Medium Term
1–3 yearsNeutral
Model confidence: 8/10
Key Factors
- Integration of Sweetwater assets driving revenue growth
- Uranium price outlook supporting royalty earnings
- Persistent high volatility and beta moderating upside
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Long‑term nuclear energy demand underpinning uranium royalties
- Strategic land and royalty portfolio across multiple jurisdictions
- Significant intrinsic value gap (price vs DCF fair value)
Key Metrics & Analysis
Financial Health
Revenue Growth416400.00%
Profit Margin8.03%
P/E Ratio132.0
ROE1.29%
ROA0.43%
Debt/Equity0.04
P/B Ratio2.1
Op. Cash Flow$39.9M
Free Cash Flow$38.0M
Industry P/E20.3
Technical Analysis
TrendNeutral
RSI56.4
Support$3.48
Resistance$4.20
MA 20$3.77
MA 50$3.73
MA 200$3.76
MACDBullish
VolumeDecreasing
Fear & Greed Index90.93
Valuation
Fair Value$10.46
Target Price$4.52
Upside/Downside14.06%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta2.00
Volatility60.35%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
KBON
Karbon Capital Partners Corp.
STOCKIAE
Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund
CLOSED_END_FUND1276
Jiangsu Hengrui Pharmaceuticals Co.,Ltd
STOCKNMTC
NeuroOne Medical Technologies Corporation
STOCK4307
Nomura Research Institute,Ltd.
STOCKNAD
Nuveen Quality Municipal Income Fund
CLOSED_END_FUNDThis analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.